Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorARENAS LAHUERTA, ENRIQUE JAVIER
dc.contributor.authorBernadó Morales, Cristina
dc.contributor.authorFernandez Navarro, Jose
dc.contributor.authorGonzalez Rodriguez, Jonatan
dc.contributor.authorMoline, Teresa
dc.contributor.authorArribas, Joaquin
dc.contributor.authorQuintana, Angela
dc.contributor.authorEsteve-Codina, Anna
dc.contributor.authorPeg, Vicente
dc.contributor.authorCortés Castan, Javier
dc.date.accessioned2023-06-06T07:27:57Z
dc.date.available2023-06-06T07:27:57Z
dc.date.issued2023-05-04
dc.identifier.citationQuintana Á, Arenas EJ, Bernadó C, Fernández Navarro J, González J, Esteve-Codina A, et al. Evaluation of triple negative breast cancer with heterogeneous immune infiltration. Front Immunol. 2023 May 4;14:1149747.
dc.identifier.issn1664-3224
dc.identifier.urihttps://hdl.handle.net/11351/9655
dc.descriptionIntratumor heterogeneity; Transcriptomics; Tumor-infiltrating lymphocytes
dc.description.abstractIntroduction: Tumor infiltrating lymphocytes (TILs) are known to be a prognostic and predictive biomarker in breast cancer, particularly in triple negative breast cancer (TNBC) patients. International guidelines have been proposed to evaluate them in the clinical setting as a continuous variable, without a clear defined cut-off. However, there are scenarios where the immune infiltration is heterogeneous that some areas of the patient’s tumour have high numbers of TILs while other areas completely lack them. This spontaneous presentation of a heterogeneous immune infiltration could be a great opportunity to study why some tumours present TILs at diagnosis but others do not, while eliminating inter patient’s differences. Methods: In this study, we have identified five TNBC patients that showed great TIL heterogeneity, with areas of low (≤5%) and high (≥50%) numbers of TILs in their surgical specimens. To evaluate immune infiltration heterogeneity, we performed and analyzed bulk RNA-sequencing in three independent triplicates from the high and low TIL areas of each patient. Results: Gene expression was homogeneous within the triplicates in each area but was remarkable different between TILs regions. These differences were not only due to the presence of TILs as there were other non-inflammatory genes and pathways differentially expressed between the two areas. Discussion: This highlights the importance of intratumour heterogeneity driving the immune infiltration, and not patient’s characteristics like the HLA phenotype, germline DNA or immune repertoire.
dc.language.isoeng
dc.publisherFrontiers Media
dc.relation.ispartofseriesFrontiers in Immunology;14
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectMarcadors tumorals
dc.subjectMama - Càncer - Prognosi
dc.subjectLimfòcits
dc.subject.meshTriple Negative Breast Neoplasms
dc.subject.meshLymphocytes, Tumor-Infiltrating
dc.subject.meshPrognosis
dc.titleEvaluation of triple negative breast cancer with heterogeneous immune infiltration
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3389/fimmu.2023.1149747
dc.subject.decsneoplasias de mama triple negativos
dc.subject.decslinfocitos infiltrantes de tumor
dc.subject.decspronóstico
dc.relation.publishversionhttps://doi.org/10.3389/fimmu.2023.1149747
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Quintana Á] Breast Cancer Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Arenas EJ] Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Biomedical Research Network Centre in Oncology (CIBERONC), Madrid, Spain. [Bernadó C] Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Fernández Navarro J, González J] Bioinformatics Department, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Esteve-Codina A] CNAG-CRG, Centre for Genomic Regulation, Barcelona Institute of Science and Technology (BIST), Barcelona, Spain. Universitat Pompeu Fabra (UPF), Barcelona, Spain. [Moliné T] Servei d’Anatomia Patològica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Peg V] Biomedical Research Network Centre in Oncology (CIBERONC), Madrid, Spain. Servei d’Anatomia Patològica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Arribas J] Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Biomedical Research Network Centre in Oncology (CIBERONC), Madrid, Spain. Departament de Medicina i Ciències de la Vida, Universitat Pompeu Fabra, Barcelona, Spain. Catalan Institution for Research and Advanced Studies, (ICREA), Barcelona, Spain. Cancer Research Program, Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Barcelona, Spain. [Cortés J] Breast Cancer Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain. International Breast Cancer Center, Pangaea Oncology, Quironsalud Group, Barcelona, Spain. Medica Scientia Innovation Research (MedSIR), Barcelona, Spain
dc.identifier.pmid37215143
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record